指南与共识前列腺增生与排尿功能障碍

P值里藏着什么?对美国泌尿外科学会良性前列腺增生指南中随机对照试验的脆弱性分析

What's in a P-Value? A Fragility Analysis of RCTs in the AUA Guidelines for Benign Prostatic Hyperplasia.
指南 / 共识 · Urology · 2023-03-07

该研究采用脆弱指数(FI)和脆弱商(FQ)评估美国泌尿外科学会(AUA)良性前列腺增生指南所引随机对照试验(RCT)中统计学显著结果的稳健性。共纳入24项RCT、分析29个结局,中位FI为12(IQR=4-38);6项研究FI≤2,10/24项RCT失访人数大于FI。作者认为指南所引RCT的稳健性优于既往泌尿外科领域脆弱性研究,但仍有改进空间。

要点

  • AUA良性前列腺增生指南373条引文中24项RCT符合纳入标准,共分析29个结局。
  • 中位脆弱指数为12(IQR=4-38),即需12个替代事件才能使结果失去统计学显著性。
  • 6项研究FI≤2,仅需改变1-2个结局即可使结果转为无统计学显著性。

核心结论

  • AUA良性前列腺增生临床实践指南所引RCT的发现稳健性优于既往评估泌尿外科领域脆弱性的研究。
  • 部分纳入研究脆弱性较高,但本分析中位FI约为同类泌尿外科RCT研究的4-5倍。
  • 作者指出仍有需要改进的领域,以支持最高质量的循证医学。

研究设计与样本

  • 两名研究者独立筛选AUA良性前列腺增生管理指南中作为推荐证据引用的RCT。
  • 研究者提取各组事件率和失访数据,并与脆弱指数进行比较。
  • 使用Stata 17.0计算FI和FQ,并按主要或次要终点汇总报告。
  • AUA指南373条引文中24项RCT符合纳入标准,共分析29个不同结局。

主要发现

  • 中位脆弱指数为12(IQR=4-38),提示需12个替代事件才能使任一研究组的统计学显著性消失。
  • 6项研究的FI≤2,提示仅需改变1-2个结局即可使结果转为无统计学显著性。
  • 10/24项RCT中,失访患者数大于脆弱指数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To use the fragility index (FI) and fragility quotient (FQ) to assess the strength of statistically significant findings for randomized controlled trials (RCTs) cited in the American Urological Association (AUA) guidelines for benign prostatic hyperplasia. METHODS: Two investigators independently screened the AUA guidelines for management of benign prostatic hyperplasia for RCTs cited as evidence for recommendations. Investigators extracted data related to event rate per group and loss to follow-up which was compared against the FI. Stata 17.0 was used to calculate the FI and FQ which was then summarized and reported according to primary or secondary endpoints. RESULTS: Among the 373 citations in the AUA guidelines, 24 RCTs met inclusion criteria with 29 distinct outcomes analyzed. The median fragility index was 12 (IQR = 4-38), indicating that twelve alternative events to either study arm would nullify statistical significance. Six studies had a FI of ≤2, indicating that only 1-2 outcomes would need to be changed in order to render nonsignificance of results. In 10/24 RCTs, the number of patients lost to follow-up was greater than the FI. CONCLUSION: The AUA Clinical Practice Guidelines for management of benign prostatic hyperplasia cite RCTs with more robust findings when compared to previous studies assessing fragility in the field of Urology. While several included studies had high fragility, the median FI in our analysis was approximately 4-5 times higher than comparable studies of urologic RCTs. However, there are areas where improvement is necessary to support the highest quality of evidence-based medicine.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Anderson RM, Peña A, Johnson BS, et al. What's in a P-Value? A Fragility Analysis of RCTs in the AUA Guidelines for Benign Prostatic Hyperplasia. Urology. 2023. PMID: 36894031. doi:10.1016/j.urology.2022.12.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。